SOM Biotech recognized as an innovative company by the Ministry of Science and Innovation

posted on July 5, 2021
SOM Biotech announces that it has obtained an INNOVATIVE SME seal from the Ministry of Science and Innovation. This distinction recognizes SOM Biotech's contribution to R&D innovation. The accreditation highlights the innovative business model, based on a pioneering computational chemistry technology that the company has developed to accelerate and streamline the drug discovery and development…
continue reading →

SOM Biotech appoints Marc Casellas as Chief Financial Officer

posted on June 28, 2021
Artificial Intelligence in Healthcare
SOM Biotech announces the appointment of Marc Casellas as Chief Financial Officer. Mr Casellas has an extensive finance experience across the healthcare and venture capital sectors, especially in providing financing to life science companies at different stages of growth. Prior to joining SOM Biotech, Marc Casellas most recently served as Chief Financial Officer of Ysios…
continue reading →

SOM Biotech to participate at the BIO International Convention 2021

posted on May 27, 2021
SOM Biotech announces its participation in the BIO International Convention 2021 on June 10th – 18th, that will take place digitally. Hosted by the Biotechnology Innovation Organisation, the event is the largest global event for the biotechnology industry that attracts the leading biotech companies, scientists, research institutions, advisors, and qualified investors, providing extensive networking and…
continue reading →

SOM Biotech to participate at the BIO-Equity Europe 2021

posted on May 13, 2021
SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotech companies as well as specialized investors in life sciences. The event enables the exchange of the latest…
continue reading →

SOM Biotech announces a presentation of the Phase 2 clinical results of SOM3355 for the treatment of chorea in Huntington´s disease

posted on April 22, 2021
SOM3355 for chorea in Huntington´s disease
SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1st – 4th 2021. The International Association for Parkinsonism and Related Disorders (IAPRD) has accepted the abstract for…
continue reading →

SOM Biotech at the “AI-Driven Drug Repositioning & Repurposing” Event

posted on April 6, 2021
AI-Driven Drug Repositioning & Repurposing
SOM Biotech will attend the “AI-Driven Drug Repositioning & Repurposing” digital congress on April 20th – 21st. Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is a game-changer in the industry,…
continue reading →